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Abstract
Fu, Tingting. M.S.E.. Department of Biomedical, Industrial and Human
Factors Engineering, Wright State University, 2012. Use of Exploratory DataMining Techniques to Analyze Associations between Bone-Mineral Density and
Relevant Clinical Parameters of Gaucher Disease.

Gaucher disease (GD) is a monogenic disorder with autosomal recessive
inheritance, which results from an acid lysosomal hydrolase, the betaglucocerebrosidase deficiency. Clinical manifestations of the disease include
anemia, thrombocytopenia, hepatosplenomegaly, and skeletal complications.
Enzyme replacement therapy (ERT) has been used to treat type 1 GD for more than
a decade, and many patients have shown remarkable clinical responses to the
treatment, with normalization of blood counts, reduction in liver and spleen size,
and improvement in bone symptoms. Many researchers have tried to study the
effectiveness of ERT, but previous research has been mainly based on some
predetermined hypotheses and traditional analysis methods, which assumed some
statistical distributions of the underlying data. In addition, studies have suggested
significant individual differences in patients’ bone mineral density (BMD)
responses to ERT.
In this project, we used non-parametric regression tree methods to analyze
the BMD data of patients with type 1 GD, in combination with other potentially
relevant parameters, including patients’ demographics, hematological, visceral, and
bone manifestations, to define a parameter subspace that explains the patients’
BMD response. Models have been derived for the patient’s initial dual-energy XIII

ray absorptiometry (DXA) Z-score, the rate of change of the patient’s DXA Zscores from his/her first infusion to the current DXA assessment visit, and the rate
of change of the patient’s DXA Z-scores between two consecutive DXA
assessment visits. Modeling results suggest that the patient’s initial DXA Z-score is
affected by his/her region, treatment with bisphosphonates, gender, and the period
between the patient’s first infusion and first DXA visit date. The rate of change of
the patient’s DXA Z-scores from his/her first infusion to the current DXA
assessment visit is mostly related to the patient’s’ region, initial DXA Z-score, and
ethnicity. In addition, the most predictive covariate of the rate of change of the
patient’s DXA Z-scores between two consecutive DXA assessment visits is the
patients’ immediately previous DXA Z-score.
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I.

Introduction

1.1 What Is Gaucher Disease?
Gaucher disease (GD) is a monogenic disorder with autosomal recessive
inheritance which results from an acid lysosomal hydrolase, the betaglucocerebrosidase deficiency. Consequently, lysosomes of the reticuloendothelial system accumulate glycolipids, creating engorged macrophages (Gaucher
cells), which displace normal tissue and result in dysfunction in many organs.
Clinical manifestations of the disease include anemia, thrombocytopenia,
hepatosplenomegaly, skeletal complications such as bone pain (BP) and bone
crisis, cortical and medullary infarctions, cortical bone thinning, medullary
expansion, osteopenia, osteolysis, osteonecrosis, and pathological fractures (Sim
et al.,2008).
Clinically, GD can be classified into three types based on the presence of
primary central nervous system involvement: type 1 GD is non-neuronopathic
which is also the most common variant; the rare type 2 GD is neuronopathic; and
type 3 GD is less common than type 1 GD and characterized by severe
visceromegaly and variably progressive neurologic involvement (Hans et al., 2008).

1.2 Enzyme Replacement Therapy and Its History
Enzyme replacement therapy (ERT) is a safe, efficacious treatment for type 1
GD, which has been used for approximately 15 years. It uses alglucerase and
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imiglucerase which are useful for treating GD, and patients’ treatment responses
can be seen within months.
Before the introduction of ERT, GD patients were mainly treated with blood
infusion, total or partial splenectomy, and the use of analgesics. In some cases of
rapidly progressing disease, patients can be treated, but at a high risk, through bone
marrow transplantation.
GD was successfully treated with ERT for the first time in the early 1990s,
using a mannose-terminated enzyme from placental tissue (alglucerase) or a
recombinant enzyme (imiglucerase, both manufactured by Genzyme, Cambridge,
MA). Most patients showed a remarkable clinical response to the treatment, with
normalization of blood counts, reduction in liver and spleen size, and improvement
in bone symptoms. At the inception of ERT, however, only a few patients could
afford the therapy because of its prohibitive costs. In order to treat more GD
patients, the European Cerezyme Access Programme (ECAP) started ERT in 2004.

1.3 Limitations of Previous Research
Although previous studies of GD have made significant contributions to ERT
research, they were based on some predetermined hypotheses and applied
traditional analysis methods, which assume some statistical distributions of the
underlying data. In addition, previous studies suggest an indispensable need for
further research on the effectiveness of ERT on GD-related bone disease, which is
the most significant cause of immobility and long-term disability for patients. Poll
et al. (2002) analyzed the lumbar spine bone-mineral density (BMD) measurements
2

of 30 GD patients enrolled in the International Collaborative Gaucher Group
(ICGG) Gaucher Registry to determine the effect of ERT. Overall, the study found
significant improvement in the BMD of the patients, yet it also showed significant
individual differences in the patients’ response to the ERT. In particular, some
patients showed rapid improvement, but others had only minor improvement in
BMD even after several years of treatment. Wenstrup et al. (2007) analyzed the
data of adult patients (men, 18–70 years; women, 18–50 years) enrolled in the
ICGG Gaucher Registry, for whom lumbar spine BMD measurements were
available to determine the effect of ERT on BMD in type 1 GD. In the study, the
sex- and age-specific reference population was first translated to the standardized
BMD and used to calculate each patient’s the dual-energy X-ray absorptiometry
(DXA) Z-scores (Hui, 1997). The major steps of the algorithm of Z-scores are: (1)
subtract the mean BMD from the individual BMD; (2) divide the result by standard
deviation of BMD. Their analysis results indicated that the DXA Z-scores for
patients with GD who received ERT improved significantly over time, approaching
the reference population. The authors also noted a significant dose–response
relationship in the ERT group. Another study led by Genzyme tested BMD
improvement after ERT in children, adolescents, and adults. A significant doseresponse relationship was noted for each age group, especially for the younger
patients. However, the study presents very slow recovery, on average, to normal Zscores values, which is the average of BMD of a healthy subject of the same age
and gender. Based on the results of these previous studies, we assume that there
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may be a combination of variables that can distinguish patients who recover bone
more quickly under ERT from those who recover bone more slowly.

1.4 Research Objective
The objective of this research is to use exploratory data mining techniques
to analyze the BMD data of patients with GD in combination with other potentially
relevant parameters, including patients’ demographics, as well as hematological,
visceral, and bone manifestations, to define a parameter subspace that explains the
BMD response.

1.5 Data Source of the Study
Data for this study were retrieved from the ICGG Gaucher Registry, which
includes patients treated with imiglucerase between the ages of 5 and 50 years. The
ICGG Gaucher Registry was first established in 1991 as a voluntary observational
database to track the clinical, biochemical and therapeutic characteristics of GD
patients, irrespective of their disease severity and treatment status. It consists of
international and regional boards of advisors, who oversee the scientific integrity of
the Gaucher Registry and who guide research, publications, policy, and the
protocols for the ICGG Gaucher Registry. The ICGG Gaucher Registry is
composed of anonymous clinical data of 4500 GD patients, which have been
submitted by over 700 physicians from 52 countries with appropriate Institutional
Review Board/Ethics Committee approval.
4

1.6 Contribution of the Research
The significance of the study lies in the fact that it is venturing into using
previously unexplored non-parametric regression methods to study the effects of
ERT on treating GD. The models resulted from the study provide valuable insights
into what demographic and clinical information of GD patients affect their BMD
responses to the treatment of GD using Imiglucerase.

1.7 Organization of the Thesis
The roadmap of the thesis is as follows. Chapter 2 reviews previous
research on the responses of GD-related bone diseases to the ERT, generalized
linear mixed models (GLMMs), the state-of-the-art modeling technique used in
previous GD research studies, data mining techniques, and methods of handling
missing data. The methods of the research are presented in chapters 3 and 4. In
particular, chapter 3 describes how the raw data retrieved from the ICGG Gaucher
Registry are preprocessed, and chapter 4 reports how models are derived from the
preprocessed data and the modeling results. Finally, in chapter 5, the conclusions
and discussion of the research are offered.
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II.

Literature Review

2.1 Responses of GD-Related Bone Disease to Enzyme Replacement Therapy
Many patients with GD suffer progressive and often disabling morbidity
attributable to skeletal complications, including osteopenia, lytic lesions,
pathological fractures, avascular necrosis, and joint destruction (Charrow et al.,
2007). Therefore, much effort has been made to study the effectiveness of ERT on
GD-related bone diseases.
Elstein et al. (1998) presented a study of examining 28 patients with varying
disease severity treated with low-dose imiglucerase for 6 to 24 months. The patients
were divided into two groups in terms of their frequencies of treatment: once every
other week or 3 times a week. The study did not find any statistically significant
difference between the two groups in the hematological parameters and
organomegaly. Although the study did not describe any quantitative data of bone
responses, it found that all the patients in the study who had GD-related bone
problems reported subjective decreases in the intensity and frequency of bone crises.
Analyzing the data of 28 pediatric patients with GD in Italy, USA and
Germany, Bembi et al. (2002) showed that the lumbar BMD of most of these
patients significantly increased after 2 years of ERT, and skeletal growth rates
increased among the patients exhibiting growth delays. This study suggests that
ERT can improve the BMD and growth rates in pediatric patients with GD.
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Poll et al. (2002) presented previous studies on the long-term effects of ERT
from six data sources, with a particular focus on the response of skeletal aspects.
This study showed a rapid response of bone marrow to ERT. In some patients,
improvement in bone marrow was detected with MRI within the ﬁrst year of
treatment, but this did not reach signiﬁcance until 4.5 years after starting ERT.
However, although the dose of ERT may be related to bone marrow response, no
significant relationship was identified in the study. In addition, the study did not
find a strong relationship between age, gender, splenectomy status or genotype and
the response of bone marrow to therapy.
Weinreb et al. (2002) analyzed data of 1,028 patients with type 1 GD,
retrieved from the Gaucher Registry, to study 2- to 5-year effects of ERT on
specific manifestations of GD, including hematologic abnormalities, organomegaly,
skeletal pain, and bone crises. The study concluded that the ERT can prevent
progressive manifestations of GD and ameliorate GD associated anemia,
thrombocytopenia, organomegaly, bone pain, and bone crises.
Tóth et al. (2003) examined 8 patients (with ages of 3-39 years) with GD
who underwent ERT for 1-8 years (30-80 IU/kg/bi-weeks/months Ceredase or
Cerezyme). The study found that the use of ERT in all the patients had led to
marked improvements in visceral and skeletal pathology of the patients.
Fost et al. (2006) conducted a retrospective comparative cohort study at 2
large European treatment centers. A total of 106 adult patients with type 1 GD, who
started ERT, were divided into 2 groups. One received ERT with an initial dose of
7

no more than 50 U/kg/4 weeks (AMC), and the other received at least 60 U/kg/4
weeks (HHU). After 12 months of ERT, there were no signiﬁcant differences
between the two groups in their increase in platelet count and hemoglobin, and
decrease in liver volume. However, patients who took the higher-dose treatment
showed a quicker and better recovery in GD-related bone diseases than those with
the lower-dose treatment.
Weinreb et al. (2007) investigated the impact of imiglucerase treatment on
health-related quality of life (HRQOL) of patients with type 1 GD and bone
involvement. 32 patients with type 1 GD with skeletal manifestations, including
bone pain, medullary infarctions, avascular necrosis, and lytic lesions, received
biweekly imiglucerase (at 60 U/kg), and the short Form-36 Health Survey (SF-36)
was administered to assess HRQOL. After 2 years of treatment, statistically
significant improvements were observed for all eight SF-36 subscales.
In Wenstrup et al. (2007), the BMD data with up to 8 years of follow-up
were analyzed for 160 patients who received no ERT and 342 patients treated with
ERT alone. These patients were enrolled in the ICGG Gaucher Registry. The DXA
Z-scores for the patients who received ERT at a dose of 60 U/kg/2 weeks were
significantly lower than those of the reference population at baseline, but they
improved significantly over time. In addition, the study also noted a significant
dose–response relationship in the ERT group of patients. In particular, the patients
who received a higher dose of ERT had faster recovery of their BMD. However,
the study also found that response to treatment was slower for BMD than for
hematologic and visceral aspects of GD.
8

Andersson et al. (2008) analyzed data from 884 children in the ICGG
Gaucher Registry to determine the effects of long-term ERT with alglucerase or
imiglucerase on hematologic and visceral manifestations, linear growth, and
skeletal disease. These patients had significant improvement in their BMD Z-score
and bone crises as well as reduction in their liver volume size and spleen size after
8 years of treatment.
With a 48-month longitudinal cohort study of 33 patients with type 1 GD in
various ethnic groups, Sims et al. (2008) reported decreases in bone pain and
skeletal complications and increases in the BMD of patients treated with
imiglucerase. In addition, independent of the patients’ genotype, hematological, and
visceral status, imiglucerase was shown to be effective for the hematological and
visceral manifestations of type 1 GD.
In Mistry et al. (2011) data of 889 patients (with ages ranging from 5 to50
years) retrieved from the ICGG Gaucher Registry were analyzed. The study found
improvement in GD–associated diseases, including bone problems. In addition, it
suggested that the improvement of BMD as a result of ERT may be greater in
younger patients than in the older adult patients.
Table 1 summarizes the 11 above reviewed previous studies on the
responses of GD-related bone disease to ERT, including the main characteristics of
the research subjects in the studies, the statistical methods used, and their main
findings.

9

Table 1. Summary of 11 Reviewed Studies on the Responses of GD-Related
Bone Disease to ERT

Article

Elstein et
al. (1998)

Bembi et
al. (2002)

Key
Characteristics of
Research
Subjects

28 patients

28 patients
Both male and
female

Poll et al.
(2002)

More than 2000
patients from 6
different data
sources, Both
male and female,
5-78 years old

Weinreb et
al. (2002)

1028 registry
patients from 25
countries United
States: 541 (53%)

Duration
of ERT

Statistical
Analysis
Method

6-24
months

two
sample ttest and
the nonparametric
MannWhitney
test

3-9 years

N/A

9 months
to more
than 8
years

N/A

2-5 years

10

mixed
model
repeatedmeasures

Main Findings
 No statistically
significant
difference
between the two
groups in the
hematological
parameters and
organomegaly.
 Lumbar BMD of
most patients
significantly
increased after 2
years of ERT
 Skeletal growth
rates increased
among the
patients
exhibiting
growth delays
 Rapid response
of bone marrow
to ERT.
 No strong
relationship was
found between
dose, age,
gender,
splenectomy
status or
genotype and
the response of
bone marrow to
therapy.
ERT can prevent
progressive
manifestations of
GD and

Western Europe:
220 (21%) Israel:
119 (12%)
elsewhere: 148
(14%)

Tóth et al.
(2003)

8 patients, 8-39
years old, both
male and female

Fost et al.
(2006)

Totally 106
patients 49
patients,
Netherlands, 2174 years old, both
male and female
57 patients,
Germany,27-82
years old, both
male and female

32 patients,
Weinreb et
less than 70 years
al. (2007)
old

Wenstrup
et al.
(2007)

342 patients,(men,
18–70 years;
women, 18–50
years)

analysis of
variance,
twosample t
tests, chisquared
test, and
Wilcoxon
rank sum
test

ameliorate GD
associated
anemia,
thrombocytopenia
, organomegaly,
bone pain, and
bone crises.

1-8 years

semiquantitativ
e method

The use of ERT
in all patients led
to marked
improvements in
visceral and
skeletal pathology
of patients with
Gaucher disease.

2-4 years

MannWhitney U
test , logrank test,
and chisquare test

The patients who
received higher
dose of ERT had
faster recovery of
their BMD.

4 years

Wilcoxon
signedrank test

8 years

linear
mixed
models
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Imiglucerase
treatment had a
significant
positive impact
on health-related
quality of life of
type 1 GD
patients with
skeletal disease,
including bone
infarctions, lytic
lesions, and
avascular
necrosis.
The DXA Zscores for the
patients who
received the ERT

Sims et al.
(2008)

33 patients, 10-70
years old, both
male and female;
Ethnicity groups:
Ashkenazi Jewish
(23 patients), NonJewish Caucasian up to 48
(6 patients),
months
AfricanAmerican/Caribbe
an (1 patient),
Hispanic (2
patients),
American Indian
12

linear
mixed
model

at a dose of 60
U/kg/2 weeks
were significantly
lower than the
reference
population at
baseline, but they
improved
significantly over
time. In addition,
the study also
noted a
significant dose–
response
relationship in the
ERT group of
patients. In
particular, the
patients who
received higher
dose of ERT had
faster recovery of
their BMD.
However, the
study also found
that response to
the treatment was
slower for BMD
than for
hematologic and
visceral aspects of
GD.
ERT decreased
the number of
bone pain and
skeletal
complications and
increased the
BMD. Despite the
patients’
genotype,
hematological,
and visceral
status, ERT was
shown to be
effective for the

(1 patient), others
(2 patients)

Andersson
et al.
(2008)

884 patients, 485
of which are under
6 years old, 260
are from 6 to 12
years old, 93 are
8 years
from 12 to 18
years old, and
others' age are
unknown

linear
mixedeffects
model

Mistry et
al. (2011)

889 patients, 5-50
years old, both
male and female

non-linear
mixed
models

over 10
years

hematological and
visceral
manifestations of
type 1 GD.
After 8 years of
ERT, most
clinical
parameters
studied (including
anemia, platelet
counts, liver and
spleen volumes
and bone crisis)
became normal or
nearly normal.
ERT resulted in
amelioration of
osteopenia in all
age groups, with
the greatest
improvements in
younger patients.

2.2 Generalized Linear Mixed Model
Table 1 suggests that the linear mixed model is the most popular statistical
method used to study the effectiveness of ERT over time. A generalized linear
mixed model (GLMM) is a parametric linear model for clustered, longitudinal,
repeated-measures data, which quantifies the relationships between multiple
predictor variables and a continuous response variable (West et al., 2007).
GLMMs can be used to analyze clustered data, such as patients in different
hospitals, and it also can be used in longitudinal or repeated-measures studies in
which subjects are measured repeatedly in different time periods, conditions, or
both (West et al., 2007).
13

A GLMM is a model of the form y=Xβ+Zu+e, where y is a vector of the
continuous dependent variable, X and Z are known design matrixes, β is a vector of
unknown regression coefficients associated with the X matrix, and u is a vector of
unknown random effects associated with the Z matrix. The vector of u is assumed
to be independent and identically distributed (IID), N (0, D). The elements on the
diagonal of the D matrix represent the variance of each random effect, and the offdiagonal elements of the D matrix are the covariance between random effects. The
vector of residuals, e, is assumed to be IID, N (0, R), and each element of the R
matrix represents the variance of a residual or covariance between two residuals.
Further, the vectors of random effects and residuals are independent from each
other.
Generally speaking, there are two approaches to building GLMMs: the topdown strategy and the set-up strategy, but the top-down strategy is often used in
most applications (West et al., 2007). The top-down strategy involves three steps.
First, we start with a model involving enough fixed effects to explain the mean
structure. Next, the random effects and residuals are added to the model. Finally,
we remove from the model the fixed-effect parameters which are not significant.
After building a GLMM, it is important to carry out model diagnostics to
check whether the assumptions for the residuals and random effects are satisfied, as
well as whether the model is sensitive to unusual observations.
Although the GLMM provides a powerful method to analyze clustered,
longitudinal and repeated-measures data, it is a rather challenging tool in many
cases. GLMM makes the analyzing process complex, which may lead to imprecise
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results. Since the estimation of unknown parameters depends on selected
model/software, it would make the process subjective.
The GLMM assumes that random effects and residuals follow multivariate
normal distributions. However, it is very difficult to check whether the multivariate
normality assumption is valid or not.
Moreover, because accurate techniques for estimating GLMM parameters
are only available in simple cases, complex GLMMs are challenging to fit.
Therefore, we cannot add too many parameters (fixed-effect and random-effect
parameters) into the GLMM, which makes this method not suitable in many
applications (Brooks, 2008).

2.3 Data Mining
Data mining (DM) is a result of the natural evolution of information
technology (http://dataminingtools.net/wiki/introduction_to_data_mining.php). A
broader view of DM considers it as a synonym for Knowledge Discovery in
Databases, or KDD. A widely accepted definition of KDD was given in Fayyard,
Piatetsky-Shapiro, and Smyth (1996): KDD is the non-trivial process of identifying
valid, novel, potentially useful, and ultimately understandable patterns in data.
Alternatively, others view data mining as simply an essential step in the process of
knowledge discovery in databases. DM is an iterative process that involves 6 main
steps: problem understanding, data understanding, data preprocessing, modeling,
evaluation, and deployment (http://www.dataminingexpertsolutions.com/dmprocess/).
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For the first two steps, users need to determine their objectives for carrying
out DM, and collect data that is related to the DM problem. Data preprocessing is
an extremely important yet often neglected step in DM, whose tasks include data
cleaning, data reduction and new data construction.
Modeling is the crucial step in the DM process where some selected data
mining algorithms are applied to the prepared dataset to extract patterns. Table 2
summarizes some common techniques used in different DM problems. After a
model is built, it is important to evaluate its performance and results with respect to
predefined objectives. Finally, if all the previous steps are satisfactory and the
models fulfill the project objectives, the DM results can then be deployed in the
problem domain.

Table 2. Common Techniques Used to Solve Different DM Problems
DM Problems

Common Techniques

Data
Description

Online Analytical Processing(OLAP), Attribute-Oriented
Approach, Statistical Approach

Dependency
Analysis

Association Rules, Correlation Analysis, Bayesian
Networks, Regression Analysis

Classification

Decision Trees, Rule Induction, Bayesian Classification,
Neural Networks,
K-Nearest Neighbors, Case-Based Reasoning

Prediction

Regress Analysis, Regression Trees, Neural Networks, KNearest Neighbors

Clustering

K-Means Methods, Hierarchical Methods, Density-Based
Methods, Neural Networks, Statistical Method, Visualization

Evolution

Trend Analysis, Sequential Pattern Mining, Periodicity
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Analysis

Analysis

Decision tree and regression tree are two of the most popular data mining
algorithms. A decision tree is a method in the form of a tree structure, which
consists of decision nodes and leaf nodes. All decision nodes have splits, testing the
values of some functions of their corresponding attributes. Each branch from the
decision node corresponds to a distinct outcome of the test. Each leaf node has a
class label attached to it. A regression tree is an extension of the decision tree
algorithm to a continuous response variable. The regression result of a leaf node in
a regression tree can be shown as a single prediction value (usually the sample
mean of all values of the response variable belonging to the leaf node), or a simple
function (usually a linear function) that relates the response variable and covariates
for the cases belonging to the leaf node, or some visual representation of the values
of the response variable in the leaf node. The tree path of a leaf node in a decision
tree or regression tree refers to the path of the tree from its root node, the top-level
node of the tree, which represents the entire dataset, to the leaf node. Each tree path
can be written in “if-then” condition statements.
Although varieties of tree algorithms have been developed with different
capabilities and requirements, most are variations of a core learning algorithm that
employs a “greedy” top-down search through the space of possible trees. The basic
procedure is as follows:
1.

Start with the root node which represents the entire training data.
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2.

If all the training data belong to the same class (in a decision tree) or have

the same values for all the predictor variables (in a regression tree), stop, and the
node becomes a leaf node.
3.

Otherwise, select the splitting attribute s, which can “best” partition the

samples based on some goodness measure of splits. This attribute becomes a
decision node.
4.

A branch is created for each category group of s if s is a categorical

variable or each interval of s if s is a continuous variable, and the samples are
partitioned accordingly.
5.

The partition process continues until some tree stopping criterion is

satisfied, such as the improvement is not substantial enough to justify further
partitioning or no predictor attribute can be further partitioned.
When building a decision tree or regression tree, pruning is an important
step to obtain a right-sized tree. Generally speaking, there are two strategies of
pruning (Murthy, 1998): (1) pre-pruning, which avoids creation of more sub-trees
by restricting the minimum node size, as well as thresholds on impurity and some
other measures; and (2) post-pruning, which creates an overfitted tree initially and
then reduces the tree size based on estimated errors.
Classification and Regression Tree (CART), which was first developed in
1980s by Breiman et al. (1984), is one of the most well-known tree algorithms. It is
a nonparametric technique that can select from among a large number of variables
and their interactions in determining the outcome variable.
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Instead of employing stopping rules, CART generates a sequence of
subtrees by first growing a full-grown tree and then pruning it back until only the
root node is left. Then it uses cross-validation to estimate the misclassiﬁcation cost
of each subtree and chooses the one with the lowest estimated cost. In particular,
CART uses the Gini index to grow a decision tree and uses the sum of squared
residuals to grow a regression tree. Finally, it uses cross-validation to estimate the
cost-complexity measure of each sub-tree (a measure combining the error and
complexity of the subtree) and chooses the one with the minimum cost-complexity.
In k-fold cross-validation, the original data sample is randomly divided
into k subsamples. One of the k subsamples is retained as the validation data for
model testing and evaluation, and the remaining (k – 1) subsamples are used as
training data for model building. The cross-validation process is then
repeated k times (the folds), with each of the k subsamples used exactly once as the
validation data. The results from the k folds then can be combined (e.g. taking the
average of the k results) to produce a single estimation.

2.4 Missing Data
Handling missing data is an important issue in this project because many
records in the original dataset of this project have missing values. This section
reviews the types of missing data mechanisms and common methods of dealing
with missing values.
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The impact of the missing data on the results of statistical analysis depends
on the mechanism that caused the data to be missing. Generally speaking, there are
3 types of missing data mechanisms (Little & Rubin, 1987): missing completely at
random (MCAR), missing at random (MAR) and missing not at random (MNAR).
MCAR means that the missing data mechanism is unrelated to the values of any
variables, whether missing or observed. MCAR is a very strong assumption
because it suggests that missing data values are random samples of all data values.
MAR is less restrictive than MCAR; it only requires the cause of the missing data
to be unrelated to the missing values but may be related to the observed values of
other variables. In other words, when MAR holds, given observed data, the
missing mechanism no longer depends on the unobserved data. If the pattern of
data missingness is non-random and the probabilities of nonresponse depend on the
missing values themselves, then the missing data are said to be MNAR.

2.5 Methods of Dealing with Missing Data
Generally speaking, methods of handling missing data can be divided into 2
broad categories: listwise deletion (discarding the records with missing values) and
missing data imputation (replacing missing data with estimated values). The first
one is easy but risky, because it can lose large amounts of information in the study
unless the incomplete cases comprise only a small fraction of all cases (Roth &
Switzer, 1995). Therefore, only imputation techniques are reviewed in this section.
Conventional imputation includes mean imputation, regression imputation,
and hot-deck imputation methods. Mean imputation, where the missing values of a
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particular variable are replaced by the mean of the observed values of the variable;
regression imputation, where missing values are imputed using the prediction from
a multiple regression analysis; and hot-deck imputation, where missing values are
replaced by the corresponding values of similar cases.
Model-based imputation procedures are advanced imputation methods
which have gained much attention recently. The basic idea of model-based methods
is to fit statistical models from observed data and then use the models to predict
missing values. We review two model-based imputation methods –Maximum
likelihood estimation and Bayesian imputation in the following paragraphs.

2.5.1

Maximum likelihood (ML) Method of Handing Missing Data
Maximum-likelihood (ML) estimation is a method of estimating parameters

in a statistical model, which also can be used in an incomplete dataset (Paul et al.,
2003).
Before discussing the ML method of treating missing data, we will review
some basic principles of ML estimates first.
Generally speaking, the basic principle of the ML method is to maximize
the estimate of parameters, given statistical models and related data. More
specifically, if we want to estimate a parameter θ, under the assumption that all
observations are identically independently distributed (IID), the likelihood for the
sample with n observations is
L ( ) =∏

,
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where Π is a symbol for repeated multiplications.
From the equation above, θ is a set of unknown parameters that drive

.

The problem then becomes to selects the values of the model parameters that
maximize the probability of the observed data. In practice, it is common to work
with the logarithm of L(θ), or ln(L(θ)), called the log-likelihood.
ML also can deal with incomplete-data in a similar way. For example, we
plan to collect data on two variables, x and y, given a sample of n independent
observations. For the first m observations, we can get data of both x and y variables;
for the n-m observations, variable x is missing data and we only collect the data of
variable y. For the observations with complete data, we present the likelihood by f
(

, where

is a set of unknown parameters that drive the distribution of x and

y. Assume x is continuous, the likelihood for entire sample is like:
∏

L ( ) =∏

;

Of the many ways to obtain maximum likelihood estimators, the
Expectation-Maximization (EM) algorithm is a very general method for estimating
the parameters with missing data (Paul et al., 2001). It also can be used to obtain
unbiased predictions for the missing values by parameters of the data model. As its
name mentioned, Expectation indicates computing expected value of complete data,
given observed data; maximization is maximizing the resulting function to obtain
unknown parameters.
The process can be divided into 3 steps: first, one should estimate the
unknown parameters, that is, the variance, covariance and means based on
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complete data (m observations) and use them to build statistical models; then
compute the missing values based on the statistical models. After all the missing
values have been imputed, the new values of unknown parameters can be obtained
by maximizing the probability of the entire dataset.
2.5.2

Bayesian Method of Treating Missing Data
An alternative approach of imputing missing data is called Bayesian method,

which is widely used in dealing with categorical missing data. Bayesian
computation in a missing data problem is based on the joint posterior distribution of
parameters and missing data, given model assumptions and observed data.
In the Bayesian method, the estimate of distribution of the parameter θ can
be made in terms of a probability statement, which is expressed as p(θ| y), and y is
observed value. The joint probability distribution of θ and y can be expressed as a
product of the prior distribution p (θ) and sampling distribution p(y|θ), respectively:
p (θ, y) = p (θ) p(y|θ). Based on Bayes’ rule, the posterior density is
p(

)=

. Since y indicates observed data, p(y) can be seen as a

constant, yielding the posterior density as p (θ |y) ∝ p (θ) p (y|θ).
Chen and Astebro (2003) proposed an easy-to-implement Bayesian modelbased approach to imputing missing categorical data, assuming the missing data
mechanism is MCAR or MAR. If the missing data mechanism is MCAR, then we
use the following procedure to impute missing data, under the assumption that the
sampling model is a multinomial distribution with the parameter θ, and
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=p(X=i,

Y=j|θ). If the missing data mechanism is MAR, we divide the value of X into r
groups based on the values of X (X=1, 2… r) and classify observed Y into these
groups. Then, we use the following procedure to impute missing data in each of
these groups.
1.

For a categorical variable Y with k possible outcomes, calculate the point

estimate for the probability of each outcome j using the formula:
=

, where

is the number of observations in the data for outcome j,

and n is the total number of observations for variable Y.
2.

Compute =∑

for all j where and j=1 to k. Note that

3.

For any observation i with a missing value, draw a random value,

the range [0, 1). If 0

=1.
from

, replace the missing value with outcome 1; if

, replace the missing value with outcome 2; …; if

, replace

the missing value with outcome k.
4.

Repeat step 3 for all missing observations of the variable.

5.

Repeat steps 1 through 4 for all other categorical variables with missing

data satisfying MCAR to form a complete data set.

2.5.3

Multiple Imputations
The imputation methods that only one value is filled for each missing data

point are called single imputation. Although they are strong techniques, single
imputations cannot reflect the sampling variability in the actual values of the
missing data under one model for non-response (Little & Rubin, 1987). Fortunately,
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there is another alternative approach—multiple imputations (MI), which can
remove these limitations.
Multiple imputations, was first proposed by Rubin in the early 1970’s as a
way to address missing data. Different from single imputation, where only one
value is filled for each missing data point, multiple imputation indicates replacing
each missing value by more than one imputed data.
Generally speaking, there are three main steps involved in multiple
imputations (Paul et al., 2001). First, we repeat the imputation procedure more than
once, producing multiple complete data sets. Second, each of these complete data
sets is analyzed using standard analysis procedures. Third, the results from these
complete data sets are combined for inference.
Rubin (1987) showed that the efficiency of an estimate based on m
imputations,

,where λ is the percentage of missing information. For

instance, with 20% missing information, m = 4 imputations can achieve bout 95%
efficiency.

III.

Data Preprocessing

Two main phases are involved in this research: data preprocessing and
model development. This chapter focuses on the first phase of the research,
describing how the raw data retrieved from the ICGG Gaucher Registry are
preprocessed before model development.
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Data preprocessing is an important yet often neglected step in data mining,
which includes data cleaning, data reduction, new data construction and data
formatting. Data cleaning is necessary when dealing with incomplete, noisy and
inconsistent data. The purpose of data reduction is to obtain a reduced dataset
which is smaller yet contains most of the important information of the complete
dataset. New data construction includes tasks such as generating new attributes
and records, merging tables, and transforming data. Data formatting involves
syntactic modifications to the data without changing its meaning. This step may
be necessary for some particular modeling tools used in the next phase of model
development.

3.1 Summary of Variables in the Raw Data
The data set from the ICGG Gaucher Registry includes 889 patients and
45 variables. Those variables can be divided into three categories based on their
features. The first category includes 27 variables related to the patients’
demographics and characteristics. The second category contains 8 variables
related to the patients’ hematological and visceral manifestations at their first
infusion of imiglucerase. The remaining 10 variables are related to the patients’
bone manifestations at their first infusion of imiglucerase. Tables 3 – 5 summarize
meaning, type, value, and the number of missing values of each variable in the
three categories, respectively.
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Table 3. Variables Related to Each Patient’s Demographics and Characteristics
Variable

Meaning

Type and values

Missing
values

REG_ID_N

patient identification

categorical (unique ID for
each patient)

0

continuous

0

date-time
date-time

0
0

binary (yes/no)

0

date-time

0

continuous

0

binary(male/female)
categorical (AfricanAmerican; AmericanIndia; Asian; Caucasian;
Hispanic; JewishAshkenazi; Jewish-Both
Ashkenzi and Sephardic;
Jewish-Neither Ashkenzi
or Sephardic; JewishSephardic; Multi-Ethnic)
categorical (Americas;
Asia, Pacific, S.Africa;
Europe; Middle East;
USA)
categorical
(N370S/N370S;N370S/Ot
her; Other/Other)
binary (never/ever
splenectomized)

0

SEX

patient’s age at first infusion (in
year)
date of the first enzyme infusion
date of a DXA assessment visit
whether the patient had
treatment with bisphosphonates
date of the treatment with
bisphosphonates
years between the first infusion
and each DXA visit date
gender

ETHGRP

patient’s ethnicity group

REGION

patient’s geographic region

GEN370S

patient’s genotype

SPLSTAT

patient’s splenectomy status

SPLDT

date of splenectomy

AGEINF
INFUSDT
VISITDT
BISPHOS
STARTDT
YRSFUP

DOSE3Y
SPINEZ
DXASP2
BSPINEZ
BSPINEZ1

average dose of imiglucerase (in
U/kg/2wks)
lumbar spine DXA Z-score
whether a patient had more than
one DXA assessment visit
whether a patient had a record
of baseline spine DXA score
whether a patient's baseline
spine DXA Z-score is equal to
or below -1

0

continuous

117
patients
(13.2%)
1 patient
(0.1%)
1 patient
(0.1%)
24 patients
(2.7%)
0

binary(yes/no)

0

binary(yes/no)

0

binary(yes/no)

0

date-time
continuous

APTOTYP

lumbar vertebrae total type

categorical (L1-L4;L2-L4)

SPINETOT

lumbar vertebrae total L1 type

continuous

DEXAMACH

measurement device

AGEGRP1

whether a patient’s age is ≥5 to
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95 patients
(10.7%)

categorical (Hologic;
Lunar)
binary (yes/no)

5 patients
(0.6%)
31 patients
(3.5%)
98 patients
(11.0%)
0

AGEGRP2
AGEGRP3
AGEGRP4
BMIB

<12
whether a patient’s age is ≥12 to
<20
whether a patient’s age is ≥20 to
<30
whether a patient’s age is ≥30 to
<50
a patient’s body mass index at
baseline

binary (yes/no)

0

binary (yes/no)

0

binary (yes/no)

0

continuous

292
patients
(32.8%)

Table 4. Variables Related to Patients’ Hematological and Visceral Manifestations
Variable

Meaning

Type and Value

HGB

hemoglobin(G/DL)

continuous

ANEM

whether a person has anemia

binary (yes/no)

PLT

platelet count(×10^3/mm^3)

continuous

THROM

thrombocytopenia category

Missing
Values
204 patients
(22.9%)
204 patients
(22.7%)
204 patients
(22.7%)
202 patients
(22.7%)
496 patients
(55.8%)
496 patients
(55.8%)
493 patients
(47.6%)
493 patients
(47.6%)

categorical (none/mild;
moderate; severe)
categorical (none/mild;
moderate; severe)

SPLENO

splenomegaly category

SPLMN

spleen volume(multiples of
normal)

integer

HEPATO

hepatomegaly category

categorical (none/mild;
moderate; severe)

LIVMIN

liver volume (multiple of normal)

integer

Table 5. Variables Related to Patients’ Bone Manifestations
Variable

Meaning

Type and Value

INFARC

presence of infraction

binary(yes/no)

EFD

presence of erlenmeyer flask
deformity

binary(yes/no)

AVN

presence of avascular necrosis

binary(yes/no)

MARR

presence of marrow infiltration

binary(yes/no)

FRACT

presence of fractures

binary(yes/no)

LYTIC

presence of lytic lesions

binary(yes/no)
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Missing Values
603 patients
(67.8%)
565 patients
(63.6%)
572 patients
(64.3%)
525 patients
(59.1%)
702 patients
(79%)
702 patients
(79%)

633 patients
(71.2%)
251 patients
(28.2%)

OSTEO

presence of osteopenia

binary(yes/no)

BPAINPM

presence of bone pain during
past month

binary(yes/no)

BPAINSEV

levels of bone pain severity

categorical(very
mild, mild,
moderate, severe,
extreme)

711 patients
(80.0%)

BCRISLS

presence of bone crises since
last submission

binary(yes/no)

471 patients
(46.9%)

3.2 Imputation of Missing Data
As shown in Tables 3 – 5, most variables in the raw data set have missing
values. Therefore, we need to decide how to handle the missing data before model
development. In this study, we imputed the missing values for three variables of
patients’ demographics and characteristics which are considered important potential
predictive variables for model development. They are ETHGRP, DOS3Y, and
BMIB.
In particular, we used the maximum likelihood (ML) method, which we
mentioned in chapter 2, to impute missing values of DOSE3Y based on REGION,
SEX, AGEINF, and SPINEZ at the patient’s first DXA assessment visit, and
impute the missing values of BMIB based on ETHGRP, SEX, and AGEINF.
Although the ML based imputation method is powerful, it also has
limitations. Because the ML method assumes that the variables involved are
normally distributed, it cannot handle categorical variables effectively. Therefore,
we used an alternative approach—Bayesian imputation to impute the missing
values of ETHGRP based on REGION and GEN370S.
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Because ETHGRP and BMIB have relatively high missing rates – 10.7%
and 32.8%, respectively, we carried out multiple imputations for them. Based on
the formula of multiple imputations described in chapter 2,

, where λ

is the percentage of missing information and m is the number of imputations, we
imputed ETHGRP twice and BMIB six times in order to achieve about 95%
efficiency in their estimates.

3.3 New Variable Construction
Although imputation is a good method of handling missing data, it cannot
handle variables with too many missing values, such as the variables related to the
patient’s hematological, visceral, and bone manifestations shown in Table1. In
order to solve this problem, we constructed 11 new variables based on the original
variables, as summarized in Table 6.

Table 6. Summary of Constructed New Variables
New Variables

Meaning
the patient’s DXA Z-score at his/her first DXA
SPINEZ_FIRST
assessment visit
the number of bi-weeks between the patient’s first
BIWEEK_FIRST_VISIT
infusion and first DXA visit date
the number of bi-weeks between the patient’s first
BIWEEK_FOLLOW_VISIT DXA assessment visit and each of his/her follow-up
DXA assessment visits
the number of bi-weeks between the patient’s
BIWEEK_CONVISIT
consecutive visits
the rate of change of the patient’s DXA Z-score from
his/her immediately previous visit to the current
visit, calculated as the patient’s DXA Z-score in the
RATE_SPINEZ
current visit subtracted from that in his/her
immediately previous visit, and then divided by the
number of bi-weeks between the two consecutive
visits (only if the patient had multiple visits)
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Type
numeric
numeric
numeric
numeric

numeric

FIRST_RATE_SPINEZ
PREVIOUS_SPINEZ

THROM_HEPATO

SPLSTAT_SPLENO

BONE_PROBLEMS

BONE_PAIN

the rate of change of the patient’s DXA Z-score from
numeric
his/her first infusion to current visit
the DXA Z-score in each patient’s immediately
numeric
previous DXA assessment visit
nonCombine THROM and HEPATO to see how many negative
of them were categorized as "severe".
Integer(0
, 1, 2)
Combine SPLSTAT and SPLENO to see whether
binary
SPLSTAT is “ever splenectomized” or SPLENO is (severe/n
“severe”. If so, SPLSTAT_SPLENO is assigned as
ot
“severe”, otherwise, it is “not severe”
severe)
nonCombine INFARC, EFD, AVN, MARR, FRACT, negative
LYTIC, and OSTEO to see how many of these
Integer
variables were reported as “yes” for a patient.
(0,1,2,3,
4,5,6,7)
Combine BPAINPM, BPAINSEV, and BCRISLS to
see whether a patient’s BPAINPM was recorded as
binary(y
“yes” and BPAINSEV as "severe" or “extreme”, or
es/no)
BCRISLS was recorded as “yes”; if so,
BONE_PAIN was assigned “yes”, otherwise, “no”.

3.4 Distributions of Selected Variables
In this section, we present the distributions of 13 variables. These variables
are AGEINF, BISPHOS, SEX, ETHGRP, REGION, DOSE3Y, SPINEZ_FIRST,
BMIB, BIWEEK_FIRST_VISIT, BIWEEK_FOLLOW_VISIT,
BIWEEK_CONVISIT, FIRST_RATE_SPINEZ, and RATE_SPINEZ. For
ETHGRP, DOSE3Y and BMIB, because we have imputed their missing values,
their distributions before and after the imputations are both illustrated in this
section.
Figure 1 illustrates the distribution of AGEINF. From this figure, we can
see the largest age group in the data set was between 5 and 10 years old. Figure 2
illustrates the distribution of BISPHOS, which shows most patients (750 out of 891
patients) did not have treatment with bisphosphonates. Figure 3 illustrates the
31

distribution of SEX, which shows that there were more female (594 out of 891
patients) than male patients. Figure 4 illustrates the distribution of REGION, which
shows that most patients were from the USA (452 of 891 patients), followed by
Europe (214 of 891 patients), the Middle East (107 of 891 patients), the Americas
(102 of 891 patients) and Asia, Pacific and South Africa (16 of 891 patients).

Figure 2. Histogram of BISPHOS

Figure 1. Histogram of AGEINF

Figure 3. Histogram of SEX

Figure 4. Histogram of REGION
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Figure 5(a) shows the distribution of ETHGRP with missing data. We can
see that the two largest ethnic groups were Caucasian and Jewish Ashkenazi, which
together accounted for about 80% of all the patients, followed by Hispanic and
African American, which accounted for about 5% and 4% of the total number of
patients, respectively. Each of the remaining groups had less than 1% of all the
patients.
Figures 5(b) and (c) illustrate the distributions of ETHGRP after the 1st and
2nd imputations, respectively. We can see their distributions are very similar to the
distribution before imputation (Figure 4); they also show that more than 80% of the
patients were Ashkenazi Jewish and Caucasian.

Figure 5 (a). Histogram of ETHGRP before Imputation
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Figure 5 (c). Histogram of ETHGRP
after the 2nd Imputation

Figure 5 (b). Histogram of ETHGRP
after the 1st Imputation

Figures 6(a) and (b) illustrate the distributions of DOSE3Y before and after
imputation, respectively. They both indicate that most patients’ dosages were
between 50 and 60 U/kg/2wks, between 20 and 30 U/kg/2wks, and between 10 and
20 U/kg/2wks.

Figure 6(b). Histogram of DOSE3Y
after Imputation

Figure 6(a). Histogram of DOSE3Y
before Imputation
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Figure 7(a) illustrates the distribution of BMIB with missing data. We can
see that the BMIB values of most patients ranged between 10 and 30. Figures 7(b)
and 7(c) illustrate the distributions of BMIB after the 1st and 2nd imputations,
respectively. In total, there are 12 imputations (2 imputations of ETHGRP × 6
imputations of BMIB) of missing data. Since all of their distributions are very
similar, only two of them are illustrated here. Comparing Figures 7(a), (b), and (c),
we can see that some of the imputed values of BMIB are below 10 whereas the
original BMIB values were always greater than 10. However, all 3 figures show
that most patients’ BMIB values fell between 10 and 30.

Figure 7(a). Histogram of BMIB before Imputation
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Figure 7(c). Histogram of BMIB after
2nd Imputation

Figure 7(b). Histogram of BMIB after
1st Imputation

Figure 8 illustrates the distribution of BIWEEK_FIRST_VISIT, which
suggests that the first DXA assessment visits of most patients occurred within 250
bi-weeks after their initial infusions. Negative values of BIWEEK_FIRST_VISIT
mean that the first DXA assessment visits of some patients occurred before their
initial infusions.
Figure 8 illustrates the distribution of BIWEEK_FOLLOW_VISIT, which
shows us that the most follow-up DXA assessment visits occurred within 250 biweeks of the first assessment visit, especially during the first 150 bi-weeks.
Figure 9 illustrates the distribution of BIWEEK_COVISIT, from which we
can see most time intervals between a patient’s two consecutive visits were less
than 50 bi-weeks, followed by between 50 and 100 bi-weeks, and between 100 and
150 bi-weeks. Very few time intervals were greater than 150 bi-weeks.
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Figure 9. Histogram of
BIWEEK_FOLLOW_VISIT

Figure 8. Histogram of
BIWEEK_FIRST_VISIT

Figure 10. Histogram of BIWEEK_COVISIT

Figure 11 illustrates the distribution of SPINEZ_FIRST, which
approximates a normal distribution, with most values ranging between -2 and 0.
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Figure 12 illustrates the distribution of FIRST_RATE_SPINEZ, which
suggests that most rates of change of a patient’s DXA Z-score from that of the first
DXA assessment visit were between -0.1 and 0.1.
Figure 13 illustrates the distribution of RATE_SPINEZ, which demonstrates
a similar pattern as that in Figure 12, with most values ranging from -0.1 to 0.1,

Figure 11. Histogram of
SPINEZ_FIRST

Figure 12. Histogram of
FIRST_RATE_SPINEZ

Figure 13. Histogram of RATE_SPINEZ
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IV.

Model Development

In this project, we focus on building models for three response variables by
using the regression tree method: SPINEZ_FIRST, which represents a patient’s
DXA Z-score at his/her first DXA assessment visit, FIRST_RATE_SPINEZ, which
is the rate of change of the patient’s DXA Z-score from his/her first infusion to the
current DXA assessment visit, and RATE_SPINEZ, which refers to the rate of
change of the patient’s DXA Z-score between two consecutive DXA assessment
visits. For each response variable, models have been derived from the 12 complete
datasets with imputed missing values, as described in chapter 3 of the thesis, as
well as from the original data set with missing values.

4.1 Regression Tree Method
Regression tree methods are used in this research to derive models from the
preprocessed data thanks to the two main advantages of regression trees over
traditional regression methods. First, it is very easy to interpret the results of a
regression tree model, because the final results of a regression model can be
summarized in a series of logical “if-then” conditions. Second, regression trees are
nonparametric and nonlinear, making no implicit assumption about the underlying
relationship between the response variable and covariates.
In particular, two regression tree algorithms with different approaches to
selecting the splitting covariate and stopping criteria are applied in this project. The
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first algorithm is the RPART package in R (Atkinson et al., 2000), which
implements many of the ideas of CART. The other algorithm is the PARTY
package in R, which selects the splitting criteria based on the theory of permutation
test and conditional distribution of statistics.
4.1.1

RPART Package

In RPART, the splitting attribute,

, is selected based on minimization of

expected sum of variances for two resulting nodes, as shown in Equation 1:
arg min
≤
where

[ var ( ) +

var ( )]

(1)

, j=1,..., M
and

represent the probabilities of cases in the left and right

nodes, respectively. var ( ) and var ( ) represent the variances of response
variable Y in the left and right child nodes, respectively. This splitting criterion is
equivalent to maximizing the between-group sum-of-squares and minimizing the
within-group sum-of-squares in the analysis of variance (ANOVA).
Like CART, RPART uses the cost-complexity function to select the best
tree size. Given a tree T with |T| leaf nodes T1, T2… T|T| and the cost of adding one
more leaf node into the model α, the cost of T is defined as follows:
(2)
where
R(T) = risk of T = ∑

(3)
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in which P(Ti) and R(Ti) represent the probability and risk of leaf node Ti,
respectively. By these definitions, selecting a tree with the “optimal” size is finding
the smallest tree T for which Rα (T) is minimized. Cross-validation is used to
choose the best value for α.
4.1.2

PARTY Package
Like most regression tree algorithms, RPART has a selection bias towards

covariates with many possible splits. The “ctree” routine in the PARTY package
addresses this problem by separating the selection of splitting covariates and
splitting points of the covariates into two distinct steps at each iteration of the tree
construction. Measuring the association between covariates and the response
variable by conditional distribution of statistics is the basis for unbiased selection
among covariates measured at different scales (Hothorn et al, 2006).
Given the responsible variable Y and m covariates (

), the

conditional distribution Y given X is:
D (Y|X) =D (Y|

)

(4)

To test whether there is dependency between Y and Xj (j = 1, 2… m), the
null hypothesis is
: D(Y| )=D(Y),

(5)

The global null hypothesis is
=
If

,

(6)

cannot be rejected at a pre-specified significance level α, the recursion

of the tree is stopped. Otherwise, the covariate with the strongest association to Y
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is selected as the splitting covariate. The association between Y and

(j=1… m) is

measured by a form of linear statistics:
(

, w)=vec(∑

(

)

)

(7)

where

is the case weight of i,

covariate

, h is the influence function, a non-random transformation of Y.

Selection of

is a non-random transformation of the

and h depends on the distributions of

( , w) depends on the joint distribution of Y and

To find the distribution of

and Y. The distribution of
.

( , w), permutation tests on each possible

permutation of the response, S ( , w) are used. The conditional expectation

and

covariance ∑ are:
=E ( ( , w)| S ( , w))

(8)

∑ =V ( ( , w)| S ( , w))

(9)

Then, we calculate the p-value of the conditional test for

on each

covariate. If the minimum of the p-values is less than a pre-specified nominal level
α,

is rejected, and the covariate with the minimum p-value is selected as a

splitting attribute. Test of the global hypothesis

can be based on univariate p-

values or multiple test procedures such as Bonferroni-adjusted p-values and the
min-p-value resampling approach.
After the splitting covariate
split of

is selected, the next step is to find the best

by evaluating all possible splits. The two-sample linear statistic, which
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measures the discrepancy between the two disjoint subsets created by a split of
A and

/A, is calculated as follows:

( , w)=vec(∑
where

,

(

)

)

(10)

(.) is the indicator function. The best split is the one that maximizes the test

statistic over all possible subsets A.

4.2 Modeling Results of SPINEZ_FIRST
The first response variable of the study is SPINEZ_FIRST, the patient’s
DXA Z-score at his/her first DXA assessment visit. We used both the RPART and
PARTY packages to build models of SPINEZ_FIRST, using 10-fold crossvalidation in RPART models and the Bonferroni-adjusted p-value of 0.95 in
PARTY models. The minimum number of records in each leaf node is set to 20
(about 2% of all the records in the data set). The 12 variables used to build the
models of SPINEZ_FIRST are summarized in Table 7.
Table 7. Variables Used to Build the Models of SPINEZ_FIRST
Variable

SEX

Meaning
patients’ age at first infusion(in
years)
whether the patient had treatment
with
bisphosphonates
gender

ETHGRP

patient's ethnicity group

AGEINF
BISPHOS
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Type and Value
numeric
binary (yes/no)
binary (male/female)
categorical (AfricanAmerican; AmericanIndian; Arab; Asian;
Caucasian; Hispanic;
Jewish- Ashkenazi;
JewishBoth Ashkenazi and
Sephardic; Jewish-

REGION

BIWEEK_FIRST_VI
SIT
DOSE3Y
BMIB
THROM_HEPATO

SPLSTAT_SPLENO

BONE_PROBLEMS

BONE_PAIN

patient's geographic region
the number of bi-weeks between first
infusion and first DXA assessment
visit
average dose of imiglucerase (in
U/kg/2wks)
a patient's body mass index at the
first infusion
combine THROM and HEPATO to
see how many of
them were categorized as "severe"
combine SPLSTAT and SPLENO to
see whether
SPLSTAT is “ever splenectomized”
or SPELNO is“severe”
combine INFARC, EFD, AVN,
MARR, FRACT, LYTIC
and OSTEO to see how many of
these variables
were reported “yes” for a patient
combine BPAINPM, BPAINSEV,
and BCRISLS to see whether for a
patient, his/her BPAINPM was
recorded as“yes” and BPAINSEV as
"severe" or “extreme”, or his/her
BCRISLS was recorded as “yes”. if
so, BONE_PAIN was assigned “yes”,
otherwise, it is “no”

Neither
Ashkenazi nor
Sephardic;
Jewish- Sephardic;
MultiEthnic)
categorical (Americas;
Asia, Pacific, S. Africa;
Europe; Middle East;
USA)
numeric
numeric
numeric
numeric (0, 1, 2)

binary
(severe/not severe)

numeric (0,1,2,3,4,5,6)

binary(yes/no)

According to the modeling results of SPINEZ_FIRST, the most predictive
variables are REGION, BISPHOS, SEX, and BIWEEK_FIRST_VISIT although
other variables included in different models vary. All the models of
SPINEZ_FIRST derived using the PARTY package are the same, as they do not
include any variable with missing values. The models of SPINEZ_FIRST derived
from the RPART package, on the other hand, are similar for the complete datasets
with the same imputed ETHGRP values but different for those with different
44

imputed BMIB values. We present 3 models derived using the RPART package
from 3 complete datasets, as well as the model derived from the original dataset
using the RPART package. The other 9 tree models derived in the study are
reported in the appendix.

4.2.1

Models of SPINEZ_FIRST by Using PARTY package
Figure 14 illustrates the regression tree model of SPINEZ_FIRST developed

using the PARTY package, in which the 3 numbers, from top to bottom, underneath
each leaf node show the number of records, the mean, and standard deviation of
SPINEZ_FIRST of the node, respectively. The model suggests that for the patients
who had bisphosphonates, female patients had significantly higher values of
SPINEZ_FIRST than male patients (t-test, p=0.0002). Among the patients who
didn’t have bisphosphonates, those in Asia, Pacific, S.Africa, Europe and the USA
had significantly higher values of SPINEZ_FRIST than those in other regions (ttest, p<0.0001). Additionally, patients who had large values of
BIWEEK_FIRST_VISIT (the number of bi-weeks between the patients’ first
infusion visits and their first DXA assessment visits) had significantly higher values
of SPINEZ_FIRST than those with smaller values of BIWEEK_FIRST_VISIT (ttest, p=0.0006).
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BISPHOS
No

Yes

REGION

SEX
Americas,
Middle East

Asia, Pacific,
S.Africa,
Europe, USA

Female

Male

BIWEEK_FIRST_VISIT
<=39

N=552
-0.669
(1.211)

N=89
-1.60
(1.061)

>39

N=93
-0.75
(1.204)

N=96
-1.103
(1.225)

N=59
-1.754
(0.852)

Figure 14. Model of SPINEZ_FIRST Derived Using the PARTY Package from All the
Individual Complete Datasets and the Original Dataset
(The 3 numbers, from top to bottom, underneath each leaf node, show the number of
records, the mean, and standard deviation of SPINEZ_FIRST of the node, respectively.)

4.2.2

Models of SPINEZ_FIRST Using the RPART Package
Figure 15 illustrates the first regression tree model of SPINEZ_FIRST

developed using the RPART package. Compared to Figure 14, Figure 15 includes
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more variables in the tree model. First, patients were divided into two groups based
on REGION. Among the patients in Europe, those who had higher values of
BIWEEK_FIRST_VISIT have significantly higher SPINEZ_FIRST values than
others. Among the patients who resided in the other regions and had
bisphosphonates, female patients had significantly higher values of
SPINEZ_FIRST than male patients. For the patients who did not have
bisphosphonates and whose values of BIWEEK_FIRST_VISIT were below 159.5,
their values of SPINEZ_FIRST values were affected by ETHGRP, AGEINF and
BMIB. More specifically, African American, Asian, both Ashkenazi and Sephardic
Jewish, neither Ashkenazi nor Sephardic Jewish, and multi-ethnic patients had
significantly smaller SPINEZ_FIRST values than those in other ethnicity groups (ttest, p=0.0003). Additionally, among the American Indian, Arab, Hispanic,
Caucasian, Jewish-Ashkenazi, and Jewish-Sephardic patients, those younger than
11 years old had significantly higher values of SPINEZ_FIRST than older patients
(t-test, p=0.0006), and those whose body mass index at their first infusion were
higher than 22.82 had significantly higher value of SPINEZ_FIRST than others (ttest, p=0.0004).
Figure 16 illustrates the second regression tree model of SPINEZ_FIRST
developed using the RPART package from a complete dataset with the same
imputed values of ETHGRP but with different imputed BMIB values, as those in
Figure 15. The major difference between Figures 15 and 16 is that BMIB has more
detailed partitions given AGEINF. Like Figure 15, Figure 16 also suggests that the
patients with higher value of BMIB had larger value of SPINEZ_FIRST.
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Figure 17 illustrates the third regression tree model of SPINEZ_FIRST
developed using the RPART package from a complete dataset with different
imputed ETHGRP values and different imputed BMIB values as those in Figure 15.
There are two major differences between Figures 15 and 17. First, for the patients
whose BIWEEK_FIRST_VISIT values were no greater than 101.5, their
SPINEZ_FIRST values were affected by their values of BMIB, particularly those
with larger values of BMIB had significantly higher values of SPINEZ_FIRST.
Second, the SPINEZ_FIRST values of female patients were affected by REGION.
More specifically, the patients in Europe had significantly lower SPINEZ_FIRST
values than the patients in other regions (t-test, p=0.0003).
Figure 18 illustrates the tree model of SPINEZ_FIRST developed using the
RPART package from the original dataset. It is very similar to Figure 17, except for
one main difference: neither Ashkenazi nor Sephardic Jewish and Multi-Ethnic
patients are grouped together with American Indian, Arab, Caucasian, Hispanic,
Sephardic Jewish, and Ashkenazi Jewish patients in Figure 18, rather than with
African American, Asian, and both Ashkenazi and Sephardic Jewish patients, as
shown in Figure 17.
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REGION
Middle East

Americas, Asia, Pacific, S. Africa, Europe, USA

BISPHOS

BIWEEK_FIRST_VISIT
Yes
<=101.5

No

BIWEEK_FIRST_VISIT

SEX

>101.5

<=159.5
Mal
e

>159.5

Female

ETHGRP
African American,
Asian, Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
multi- Ethnic

American Indian, Arab,
Hispanic, Caucasian,
Jewish-Ashkenazi,
Jewish-Sephardic

AGEINF
<=11

>11

BMIB
<=22.82

N=81
-1.717
(1.058)

N=32
-0.898
(1.260)

N=49
-1.683
(0.831)

N=78
-0.964
(1.218)

>22.82

N=44
N=87
N=200 N=174 N=144
-1.343 -0.359 -1.055 -0.617
-0.387
(1.103) (1.185) (1.212) (1.094) (1.223)

Figure 15. Model 1 of SPINEZ_FIRST Derived Using the RPART Package from a
Complete Dataset
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REGION
Americas, Asia, Pacific, S. Africa, Europe,
USA

Middle East

BISPHOS

BIWEEK_FIRST_VISIT
Yes
<=101.5

>101.5

No

BIWEEK_FIRST_VISIT

SEX

<=159.5

Male

>159.5

Female

ETHGRP
African American,
Asian, Jewish
(both Ashkenazi
and Sephardic),
Jewish (neither
Ashkenazi nor
Sephardic), multiEthnic

American Indian,
Arab, Hispanic,
Caucasian, JewishAshkenazi, JewishSephardic

AGEINF
<=11

BMIB
<=18.0

>11

BMIB
>18.0 <=19.2

>19.2

N=81
N=32 N=49
N=78 N=44
N=62 N=25 N=89 N=285 N=144
-1.717 -0.898 -1.683 -0.964 -1.343 -0.615 -0.276 -1.314 -0.706 -0.387
(1.058) (1.260) (0.831) (1.218) (1.103) (1.136) (1.075) (1.151) (1.150) (1.223)
Figure 16. Model 2 of SPINEZ_FIRST Derived Using the RPART Package from a
Complete Dataset
(The complete dataset has the same imputed ETHGRP values as those used in Figure 15
but with different imputed BMIB values.)
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REGION
Middle East

Americas, Asia, Pacific, S. Africa, Europe, USA

BIWEEK_FIRST_VISIT

BISPHOS
Yes

<=101.5

No

BIWEEK_FIRST_VISIT

SEX

>101.5

Male

>159.5

<=159.5

Female

ETHGRP
African American,
Asian, Jewish
(both Ashkenazi
and Sephardic),
Jewish (neither
Ashkenazi nor
Sephardic), multiEthnic

American Indian,
Arab, Hispanic,
Caucasian,
Jewish-Ashkenazi,
Jewish-Sephardic

AGEINF
REGION

BMIB
<=20.76

<=11
Middle East,
Americas,
Asia, Pacific,
S.Africa , USA

Europe
>20.76

>11

BMIB
<=19.77

>19.77

N=30 N=51 N=32 N=49 N=14 N=64 N=44 N=87 N=96 N=287 N=144
-2.291 -1.380 -0.898 -1.683 -1.800 -0.781 -1.343 -0.359 -1.245 -0.715 -0.387
(0.806) (1.050) (1.260) (0.831) (0.776) (1.225) (1.103) (1.185) (1.204) (1.139) (1.223)
Figure 17. Model 3 of SPINEZ_FIRST Derived Using the RPART Package from a
Complete Dataset
(The complete dataset has different imputed ETHGRP and BMIB values from those used
in Figures 15 and 16.)
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REGION
Americas, Asia, Pacific, S. Africa, Europe, USA

Middle East

BIWEEK_FIRST_VISIT

BISPHOS
Yes

No

BIWEEK_FIRST_VISIT

SEX
>101.5

<=101.5

<=159.5
Male

Female

>159.5

ETHGRP
Jewish-Sephardic,
Arab, Hispanic,
Caucasian,
Jewish-Ashkenazi,
American Indian,
Jewish (neither
Ashkenazi nor
Sephardic), MultiEthnic

African
American,
Asian, Jewish
(both Ashkenazi
and Sephardic)

AGEINF
BMIB

<=11

>11

BMIB
<=20.5

>20.5

N=20
N=39
-2.316 -1.424
(0.923) (1.103)

<=19.77

N=32
-0.898
(1.260)

N=49
-1.683
(0.831)

>19.77

N=78
N=23
N=78 N=57
N=179 N=144
-0.964 -1.707 -0.306 -1.418 -0.700 -0.387
(1.219) (1.118) (1.187) (1.043) (1.145) (1.223)

Figure 18. Model 4 of SPINEZ_FIRST Derived Using the RPART Package from the
Original Dataset

52

4.3 Modeling Results of FIRST_RATE_SPINEZ
Only the patients who had at least two DXA assessment visits are used to
build models of FIRST_RATE_SPINEZ. In addition, 3 outliers whose values of
FIRST_RATE_SPINEZ were greater than 0.15 or less than -0.15 are removed. As a
result, only data from 471 patients with 1066 records are used to build models of
FIRST_RATE_SPINEZ.
The variables used to build the models of FIRST_RATE_SPINEZ are
summarized in Table 8. In addition to the variables used to build the models of
SPINEZ_FIRST, as listed in Table 7, the response variable discussed in section 4.2
is also included as a predictor in building the models of FIRST_RATE_SPINEZ.
Besides, FIRST_BIWEEK_UP, the number of bi-weeks between a patient’s first
DXA assessment visit and each of his/her follow-up DXA assessment visits, is
another new variable in the models of FIRST_RATE_SPINEZ.
Table 8. The Variables Used in Building Models of FIRST_RATE_SPINEZ
Variable

SEX

Meaning
patients’ age at first infusion(in
years)
whether the patient had treatment
with
bisphosphonates
gender

ETHGRP

patient's ethnicity group

REGION

patient's geographic region

AGEINF
BISPHOS
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Type and Value
numeric
binary (yes/no)
binary (male/female)
categorical (AfricanAmerican; AmericanIndian; Arab; Asian;
Caucasian; Hispanic;
Jewish- Ashkenazi;
JewishBoth Ashkenazi and
Sephardic; Jewish-Neither
Ashkenazi nor Sephardic;
Jewish- Sephardic; MultiEthnic)
categorical (Americas;

Asia, Pacific, S. Africa;
Europe; Middle East;
USA)
BIWEEK_
FOLLOW_VISIT
DOSE3Y
BMIB
THROM_HEPATO

SPLSTAT_SPLENO

BONE_PROBLEMS

BONE_PAIN

SPINEZ_FIRST

4.3.1

the number of bi-weeks between each
patient’s first DXA Z-Score visit and
each of the following-up DXA ZScore visits
average dose of imiglucerase (in
U/kg/2wks)
a patient's body mass index at the
first infusion
combine THROM and HEPATO to
see how many of
them were categorized as "severe"
combine SPLSTAT and SPLENO to
see whether
SPLSTAT is “ever splenectomized”
or SPELNO is“severe”
combine INFARC, EFD, AVN,
MARR, FRACT, LYTIC, and
OSTEO to see how many of these
variables were reported “yes” for a
patient
combine BPAINPM, BPAINSEV,
and BCRISLS to see whether for a
patient, his/her BPAINPM was
recorded as“yes” and BPAINSEV as
"severe" or “extreme”, or his/her
BCRISLS was recorded as “yes”. if
so, BONE_PAIN was assigned “yes”,
otherwise, it is “no”
the DXA Z-Score at each patient’s
first DXA assessment visit.

numeric

numeric
numeric
numeric (0, 1, 2)

binary
(severe/not severe)

numeric (0,1,2,3,4,5,6)

binary(yes/no)

numeric

Models of FIRST_RATE_SPINEZ Using PARTY Package
Figure 19 illustrates the model of FIRST_RATE_SPINEZ developed using

the PARTY package from the 12 complete datasets and from the original dataset,
which suggests that the patients with higher SPINEZ_FIRST values had
significantly lower FIRST_RATE_SPINEZ values than those with lower
SPINEZ_FIRST values. In particular, most patient whose SPINEZ_FIRST values
were greater than 0.36 had negative FIRST_RATE_SPINEZ values, and the
patients in Europe had significantly lower FIRST_RATE_SPINEZ values than
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those in other regions (t-test, p<0.0001). For the patients in Americas, Asia, Middle
East, USA, Pacific, and S. Africa, whose SPINEZ_FIRST values ranged from -2.7
to 0.36, their values of FIRST_RATE_SPINEZ were related to SEX, AGEINF,
BIWEEK_ FIRST_VISIT, BISPHOS, and ETHGRP. In particular, Asian,
Caucasian, Ashkenazi Jewish, both Ashkenazi and Sephardic Jewish, neither
Ashkenazi nor Sephardic Jewish, and Multi-Ethnic patients had significantly
smaller FIRST_RATE_SPINEZ values than the patients in other ethnic groups (ttest, p<0.0001). Among these patients, those who had bisphosphonates had
significantly lower FIRST_RATE_SPINEZ values than those without (t-test,
p<0.0001). Male patients had significantly lower values of FIRST_RATE_SPINEZ
than female patients (t-test, p<0.0001). Among these female patients, those with
lower values of BIWEEK_ FOLLOW_VISIT tended to have higher values of
FIRST_RATE_SPINEZ.
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SPINEZ_FIRST
<=0.36

>0.36

SPINEZ_FIRST
<=-2.66

REGION

>-2.66
Europe

REGION
Europe

Americas, Asia, Pacific,
S.Africa, Middle East,
USA

Americas,
Asia,
Middle
East, USA

ETHGRP
Asian, Caucasian, JewishAshkenazi, Jewish (both Ashkenazi
and Sephardic), Jewish (neither
Ashkenazi nor Sephardic), MultiEthnic

African
American,
American
Indian, Arab,
Hispanic

BISPHOS

No

Yes

SPINEZ_FIRST

SEX
Male

Female

<=-1.72

>-1.72

BIWEEK_ FOLLOW_VISIT

>35

<=35

SPINEZ_FIRST
<=-0.95

>-0.95

N=84 N= 204 N=72 N=193 N=53 N=105 N=80 N=42 N=87 N=56 N=90
0.014 -0.002 0.012 0.002 0.011 0.006 0.003 0.006 -0.003 -0.020 -0.001
(0.019) (0.016) (0.021) (0.016) (0.014) (0.006) (0.005) (0.008) (0.014) (0.027) (0.014)
Figure 19. Model of FIRST_RATE_SPINEZ Derived Using the PARTY Package from the
12 Complete Datasets and from the Original Dataset.
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4.3.2

Models of FIRST_RATE_SPINEZ Using RPART Package
Figure 20 illustrates the model of FIRST_RATE_SPINEZ developed using

the RPART package from the 12 complete datasets. From the figure, we can see
that SPINEZ_FIRST and REGION are two most predictive variables of
FIRST_RATE_SPINEZ. Most patients whose SPINEZ_FIRST values were larger
than 0.36 had negative FIRST_RATE_SPINEZ values. For the patients whose
SPINEZ_FIRST values ranged from -2.7 to 0.36, their values of
FIRST_RATE_SPINEZ were related to ETHGRP and REGION. More specifically,
African American, American Indian, Arab, and Hispanic patients had significantly
higher FIRST_RATE_SPINEZ values than the other patients (t-test, p<0.0001).
Among the Asian, Caucasian, Ashkenazi Jewish, both Ashkenazi and Sephardic
Jewish, neither Ashkenazi nor Sephardic Jewish, and multi-Ethnic patients, those in
Europe had significantly lower values of FIRST_RATE_SPINEZ than those in
other regions (t-test, p<0.0001).
Figure 21 illustrates the model of FIRST_RATE_SPINEZ developed using
the RPART package from the original dataset. It is very similar to Figure 20, except
for one difference: compared to Figure 20, Figure 21 had an additional predictor
BMIB in the model. Among the patients in the Americas, Asia, Pacific, S. Africa,
Middle East and the USA, those whose BMIB values were greater than 15.5 had
significantly higher value of FIRST_RATE_SPINEZ than those in other regions (ttest, p<0.0001).
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SPINEZ_FIRST
>0.37

>0.37

REGION

SPINEZ_FIRST
>-2.66

<=-2.66

Europe

ETHGRP
Asian, Caucasian,
Jewish-Ashkenazi,
Jewish-Sephardic,
Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
Multi-Ethnic

Americas, Asia,
Pacific, S.Africa,
Middle East, USA

African American,
American Indian,
Arab, Hispanic

REGION
Europe

N=84
0.014
(0.019)

N=204
-0.002
(0.016)

Americas, Asia,
Pacific, S.Africa,
Middle East, USA

N=560
0.003
(0.013)

N=72
0.012
(0.022)

N=56
-0.020
(0.0267)

N=90
-0.001
(0.014)

Figure 20. Model of FIRST_RATE_SPINEZ Derived Using the RPART Package
from All the Complete Datasets
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SPINEZ_FIRST
<=0.36

>0.36

REGION

SPINEZ_FIRST
>-2.66

<=-2.66

Europe

ETHGRP
Asian, Caucasian,
Jewish-Ashkenazi,
Jewish-Sephardic,
Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
Multi-Ethnic

African American,
American Indian,
Arab, Hispanic

Americas,
Asia, Pacific,
S.Africa,
Middle East,
USA

REGION
Europe

Americas, Asia,
Pacific, S.Africa,
Middle East, USA

BMIB

N=84
0.013
(0.019)

N=177
-0.003
(0.017)

<=15.5

>15.5

N=25
-0.006
(0.020)

N=362
0.004
(0.013)

N=58
0.012
(0.022)

N=56
-0.020
(0.027)

N=90
-0.001
(0.014)

Figure 21. Model of FIRST_RATE _ SPINEZ Derived Using the RPART Package from
the Original Dataset
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4.4 Modeling Results of RATE_SPINEZ
Like the dataset used to build the models of FIRST_RATE_SPINEZ, the
dataset used to build the models of RATE_SPINEZ also only contains the patients
who had multiple DXA assessment visits. Besides, 2 outliers whose
RATE_SPINEZ values are larger than 0.2 or smaller than -0.2 are removed. As a
result, data from 471 patients with 1067 records are used to derive models of
RATE_SPINEZ.
Table 9 summarizes the variables used to build the models of
RATE_SPINEZ. Compared to Table 8, Table 9 does not include
FIRST_BIWEEK_UP or SPINEZ_FIRST, but it contains PREVIOUS_ SPINEZ,
which represents the patient’s DXA Z-score at his/her immediately previous DXA
assessment visit, and BIWEEK_COVISIT, which refers to the number of bi-weeks
between the patient’s two consecutive DXA assessment visits.
Table 9. Variables Used to Build Models of RATE_SPINEZ
Variable

SEX

Meaning
patients’ age at first infusion (in
years)
whether the patient had treatment
with
bisphosphonates
gender

ETHGRP

patient's ethnicity group

REGION

patient's geographic region

AGEINF
BISPHOS
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Type and Value
numeric
binary (yes/no)
binary (male/female)
categorical (AfricanAmerican; AmericanIndian; Arab; Asian;
Caucasian; Hispanic;
Jewish- Ashkenazi;
JewishBoth Ashkenazi and
Sephardic; Jewish-Neither
Ashkenazi nor Sephardic;
Jewish- Sephardic; MultiEthnic)
categorical (Americas;

Asia, Pacific, S. Africa;
Europe; Middle East;
USA)
BIWEEK_COVISIT
DOSE3Y
BMIB
THROM_HEPATO

SPLSTAT_SPLENO

BONE_PROBLEMS

BONE_PAIN

PREVIOUS_SPINEZ

the number of bi-weeks between
two successive DXA Z-Score visits
average dose of imiglucerase (in
U/kg/2wks)
a patient's body mass index at the
first infusion
combine THROM and HEPATO to
see how many of
them were categorized as "severe"
combine SPLSTAT and SPLENO
to see whether
SPLSTAT is “ever splenectomized”
or SPELNO is“severe”
combine INFARC, EFD, AVN,
MARR, FRACT, LYTIC
and OSTEO to see how many of
these variables
were reported “yes” for a patient
combine BPAINPM, BPAINSEV,
and BCRISLS to see whether for a
patient, his/her BPAINPM was
recorded as“yes” and BPAINSEV
as "severe" or “extreme”, or his/her
BCRISLS was recorded as “yes”. if
so, BONE_PAIN was assigned
“yes”, otherwise, it is “no”
the DXA Z-Score in each patient’s
immediately previous DXA
assessment visit

numeric
numeric
numeric
numeric (0, 1, 2)

binary
(severe/not severe)

numeric (0,1,2,3,4,5,6)

binary(yes/no)

numeric

The models of RATE_SPINEZ developed using the PARTY and RPART
packages are much simpler than the models of the other two response variables. All
the models of RATE_SPINEZ suggest that PREVIOUS_SPINEZ is the most
predictive variable of RATE_SPINEZ.
4.4.1

Models of RATE_SPINEZ Developed Using the PARTY Package
Figure 22 illustrates the model of RATE_SPINEZ developed using the

PARTY package from all of the 12 complete datasets and from the original dataset,
which suggests that PREVIOUS_SPINEZ is the only important predictive variable
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of RATE_SPINEZ. Particularly, the lower the PREVIOUS_SPINEZ, the higher the
RATE_SPINEZ.

PREVIOUS_SPINEZ

<=-2.55

>2.55

PREVIOUS_SPINEZ

N=84
0.018
(0.031)

<=-0.72

>-0.72

N=517
0.005
(0.022)

N=466
-0.002
(0.023)

Figure 22. Model of RATE_SPINEZ Derived Using the PARTY Package from All the
Individual Complete Datasets and from the Original Dataset

4.4.2

Models of RATE_SPINEZ Developed Using the RPART Package
Figure 23 illustrates the model of RATE_SPINEZ developed using the

RPART package from all the complete datasets. It suggests that most patients
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whose BIWEEK_COVISIT values were less than 14.5 had negative values of
RATE_SPINEZ. Otherwise, for the patients whose BIWEEK_COVISIT values
were greater than 14.5, and PREVIOUS_SPINEZ values were less than -2.595,
their values of RATE_SPINEZ are affected by ETHGRP. More specifically,
African American, Ashkenazi Jewish, and Multi-Ethnic patients had significantly
lower values of RATE_SPINEZ than the other patients (t-test, p<0.0001). For the
patients in the other ethnicity groups, whose BIWEEK_COVISIT values were more
than 14.5, their RATE_SPINEZ values were only related to PREVIOUS_SPINEZ:
the lower the PREVIOUS_SPINEZ, the higher the RATE_SPINEZ.
Figure 24 illustrates the model developed from the original dataset using the
RPART package. It is almost identical to Figure 23, except with one difference:
ETHGRP in Figure 23 is replaced by BMIB in Figure 24. In particular, the patients
with BMIB values less than 22.5 had significantly lower values of RATE_SPINEZ
than those with higher BMIB values.
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BIWEEK_COVISIT
>14.5

<=14.5

PREVIOUS_SPINEZ
<=-1.495

>-1.495

PREVIOUS_SPINEZ
<=-2.595

>-2.595

ETHGRP
African-American,
Jewish-Ashkenazi,
Multi-ethnic

N=29
-0.027
(0.046)

N=39
0.009
(0.020)

Asian, Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
American Indian,
Arab, Hispanic,
Caucasian

N=40
0.028
(0.038)

N=255
0.007
(0.022)

N=704
0.0004
(0.020)

Figure 23. Model of RATE_SPINEZ Derived Using the RAPRT Package from All the
Complete Datasets
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BIWEEK_COVISIT
<=14.5

>14.5

PREVIOUS_SPINEZ
<=-1.495

>-1.495

PREVIOUS_SPINEZ
>-2.595

<=-2.595

BMIB
<=22.5

N=29
-0.027
(0.046)

N=79
0.018
(0.032)

N=141
0.007
(0.021)

>22.5

N=47
0.018
(0.034)

N=704
0.0004
(0.020)

Figure 24. Model of RATE_SPINEZ Derived Using the RAPRT Package from the
Original Dataset

4.5 Summary of Key Findings
We summarize the key findings from the derived models of
SPINEZ_FIRST, FIRST_RATE_SPINEZ and RATE_SPINEZ.
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4.5.1

Findings of SPINEZ_FIRST
All the models of SPINEZ show that the most predictive variables of

SPINEZ_FIRST are REGION (the patient’s geographic region), BISPHOS
(whether the patient had bisphosphonates), SEX (patients’ gender) and
BIWEEK_UP_FIRST (the number of bi-weeks between the patient’s first infusion
and his/her first DXA assessment visit). More details are as follows:


Patients who had larger values of BIWEEK_UP_FIRST had significantly
larger values of SPINEZ_FIRST than those with smaller values of
BIWEEK_UP_FIRST.



Among the patients in Middle East, their values of SPINEZ_FIRST were
affected by BIWEEK_UP_FIRST. Those with larger values of
BIWEEK_UP_FIRST had higher values of SPINEZ_FIRST.



Among the patients who had bisphosphonates, their values of
SPINEZ_FIRST were affected by SEX. Particularly, female patients had
significantly higher values of SPINEZ_FIRST than male patients.

4.5.2

Models of FIRST_RATE_SPINEZ
All the models of FIRST_RATE_SPINEZ suggest that the most predictive

variables of FIRST_RATE_SPINEZ are REGION, SPINEZ_FIRST, and ETHGRP.
More details are listed as follows:
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Patients with smaller SPINEZ_FIRST values had significantly higher values
of FIRST_RATE_SPINEZ than the patients with larger SPINEZ_FIRST
values.



Patients with SPINEZ_FIRST less than -2.66 had the largest
FIRST_RATE_SPINEZ, while most patients with SPINEZ_FIRST greater
than 0.36 had negative FIRST_RATE_SPINEZ.



For the patients with SPINEZ_FIRST ranging between -2.66 and 0.36, their
values of FIRST_RATE_SPINEZ were affected by REGION and ETHGRP.
Those in Europe had significantly lower values of FIRST_RATE_SPINEZ
than those in other regions. In addition, African American, American Indian,
Arab, and Hispanic patients had significantly larger values of
FIRST_RATE_SPINEZ than the other patients.

4.5.3

Models of RATE_SPINEZ
All the models of RATE_SPINEZ suggest that the most predictive variables

of RATE_SPINEZ is PREVIOUS_SPINEZ. In particular, patients with smaller
PREVIOUS_SPINEZ had greater RATE_SPINEZ than those with larger
PREVIOUS_SPINEZ.

V.

Discussion and Conclusions

In this research, we have applied two regression tree methods – RPART and
PARTY packages in R – to build models for three response variables:
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SPINEZ_FIRST, FIRST_RATE_SPINEZ, and RATE_SPINEZ. For each response
variable, models have been derived from 12 complete datasets that contain
variations of imputed values for missing covariates, as well as from the original
data set with missing values. The regression trees may have different structures by
using different methodologies, because of the variations in the imputed values of
ETHGRP and BMIB, and different approaches to selecting splits and stopping rules
in RPART and PARTY packages, the derived models were consistent in terms of
the most predictive covariates of the response variable. In particular, the most
predictive covariates of SPINEZ_FIRST are REGION, BISPHOS, SEX and
BIWEEK_UP_FIRST, the most predictive covariates of FIRST_RATE_SPINEZ
are REGION, SPINEZ_FIRST, and ETHGRP, and the most predictive covariate of
RATE_SPINEZ is PREVIOUS_SPINEZ.
The modeling results of SPINEZ_FIRST suggest that the longer the
duration between a patient’s first infusion of imiglucerase and his/her first DXA
assessment visit is, the larger the patient’s bone-mineral density tends to be. It can
be assumed that most patients had a relatively low bone density at the beginning of
the treatment, and it takes some time before the patients can benefit from the ERT
treatment. Therefore, if there was a longer period between the start of the treatment
and the first DXA assessment, the beneficial effect of the treatment could manifest
itself for a longer period, and the bone-mineral density would be higher as a result.
For those who had the treatment with bisphosphonates, female patients
tended to have higher initial bone-mineral density than male patients.
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Regarding the rate of change in a patient’s DXA Z-score between the
patient’s first infusion and each of his/her following DXA assessment visits, the
models suggest that the patients with a lower value of bone-mineral density at the
beginning of the treatment caught up to the normal level of bone-density more
quickly. It is also interesting to notice that among the patients whose initial DXA Zscore values were from -2.66 to 0.36, those from Europe profited less from the
treatment than the patients from other regions.
When the rate of bone-mineral density change between successive
measurements is evaluated, the most predictive variable is the previous bonemineral density value. In particular, patients with lower previous bone-mineral
density had more improvement from the treatment. This is again consistent with the
theory that patients with lower bone-mineral density have more of a need to catch
up.
Another interesting finding is that the treatment dosage only appears twice
in the models of FIRST_SPINEZ, and it only affects Arab, Hispanic, Caucasian,
Jewish-Ashkenazi, Jewish-Sephardic, and American Indian patients. Among these
patients, a higher dosage led to faster improvement of bone-mineral density in
general.
None of the new variables constructed from patient’s hematological,
visceral, and bone manifestations show up as important predictive covariates of the
three response variables studied in the research.
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APPENDIX. Models of SPINEZ_FIRST
This appendix contains 9 models of SPINEZ_FIRST derived using the RPART package
from complete datasets, which are not concluded in 4.2.2 of the report.

REGION
Middle East

Americas, Asia, Pacific, S. Africa, Europe,
USA

BIWEEK_FIRST_VISIT

BISPHOS
No

Yes
<=101.5

>101.5

BIWEEK_FIRST_VISIT

SEX

<=159.5

Male

>159.5

Female

ETHGRP
African American,
Asian, Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
Multi-Ethnic

Jewish-Sephardic,
Arab, Hispanic,
Caucasian, JewishAshkenazi, American
Indian

AGEINF
>11

<=11
BIWEEK_FIRST_VISIT
<=156.5

>156.5

BMIB
>19.77

<=19.77
DOSAGE
<=52.5

>52.5

N=81 N=32 N=49 N=54 N=20 N=44 N=87 N=102 N=66 N=202 N=144
-1.717 -0.898 -1.683 -1.189 -0.31375-1.343 -0.359 -0.928 -1.438 -0.625 -0.387
(1.058) (1.260)(0.831) (1.020) (1.515) (1.103) (1.185) (1.144) (1.132)(1.142) (1.223)

REGION
Americas, Asia, Pacific, S. Africa,
Europe,USA

Middle East

BIWEEK_FIRST_VISIT

BISPHOS
Yes

No

BIWEEK_FIRST_VISIT

SEX
<=101.5

>101.5
<=159.5
Male

Female

>159.5

ETHGRP

African American,
Asian, Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
Multi-Ethnic

Jewish-Sephardic, Arab,
Hispanic, Caucasian,
Jewish-Ashkenazi,
American Indian

AGEINF
<=11

>11

BMIB
<=21.0
2

N=81
-1.717
(1.058)

N=32
-0.898
(1.260)

N=49
N=78
-1.683 -0.964
(0.831) (1.218)
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N=44 N=87
N=153
-1.343 -0.359 -1.130
(1.103) (1.185) (1.220)

>21.02

N=221
-0.658
(1.109)

N=144
-0.387
(1.223)

REGION
Americas, Asia, Pacific, S. Africa,
Europe, USA

Middle East

BIWEEK_FIRST_VISIT

BISPHOS
Yes

No

BIWEEK_FIRST_VISIT

SEX
<=101.5

>101.5
<=159.5
Male

>159.5

Female

ETHGRP
African American,
Asian, Jewish (both
Ashkenazi and
Sephardic),
Jewish (neither
Ashkenazi nor
Sephardic), MultiEthnic

Jewish-Sephardic,
Arab, Hispanic,
Caucasian, JewishAshkenazi,
American Indian

AGEINF
<=11

>11

AGEINF
<=21.5

N=81
N=32
N=49 N=78
N=44 N=87
N=91
-1.717 -0.898 -1.683 -0.964 -1.343 -0.359
-1.233
(1.058) (1.260) (0.831) (1.218) (1.103) (1.185) (1.207)
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>21.5

N=283
-0.728
(1.143)

N=144
-0.387
(1.223)

REGION

Americas, Asia, Pacific, S. Africa,
Europe, USA

Middle East

BIWEEK_FIRST_VISIT

BISPHOS
No

Yes
<=101.5

BIWEEK_FIRST_VISIT

SEX

>101.5

>159.5

<=159.5
Male

Female

ETHGRP

African American,
Asian, Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),

Jewish-Sephardic,
Arab, Hispanic,
Caucasian, JewishAshkenazi,
American Indian

Multi-Ethnic

AGEINF
<=11

>11

BIWEEK_FIRST_VISIT

BMIB

BMIB
<=156.5

<=20.76

>156.5

<=19.77

>19.77

>20.76
DOSAGE
<=52.5

>52.5

N=30 N=51 N=32 N=49 N=58 N=20 N=44 N=87 N=58 N=38 N=278 N=144
-2.291 -1.380 -0.898 -1.683 -1.189 -0.313 -1.343 -0.359 -0.996 -1.626 -0.715 -0.387
(0.806) (1.050) (1.260) (0.831) (1.020) (1.51) (1.103) (1.185) (1.221)(1.084)(1.139) (1.223)
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REGION

Americas, Asia, Pacific, S. Africa, Europe,
USA

Middle East

BISPHOS

BIWEEK_FIRST_VISIT
Yes

No

BIWEEK_FIRST_VISIT

SEX
<=101.5

<=159.5

>101.5
Male

Female

>159.5

ETHGRP
Jewish-Sephardic,
Arab, Hispanic,
Caucasian, JewishAshkenazi,
American Indian

African American,
Asian, Jewish
(both Ashkenazi
and Sephardic),
Jewish (neither
Ashkenazi nor
Sephardic), MultiEthnic

AGEINF
<=11

>11

BMIB
<=21.02

N=81
-1.717
(1.058)

N=32
-0.898
(1.260)

N=49
-1.683
(0.831)

>21.02

N=78
N=44
N=87
N=153 N=221 N=144
-0.964 -1.343 -0.359
-1.130 -0.658 -0.387
(1.218) (1.103) (1.185) (1.220) (1.109) (1.223)
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REGION

Americas, Asia, Pacific, S. Africa, Europe,
USA

Middle East

BIWEEK_FIRST_VISIT

BISPHOS
Yes

No

BIWEEK_FIRST_VISIT

SEX
<=101.5

>101.5

Male

<=159.5

Female

>159.5

ETHGRP
African American,
Asian, Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
Multi-Ethnic

Jewish-Sephardic,
Arab, Hispanic,
Caucasian, JewishAshkenazi,
American Indian

AGEINF
<=11

>11

BMIB
<=19.23

N=81
N=32
-1.717 -0.898
(1.058) (1.260)

N=49
N=78
-1.683 -0.964
(0.831) (1.218)

N=44
N=87
N=89
-1.343
-0.359
-1.314
(1.103) (1.185) (1.151)
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>19.23

N=285
-0.706
(1.150)

N=144
-0.387
(1.223)

REGION
Americas, Asia, Pacific, S. Africa, Europe, USA

Middle East

BIWEEK_FIRST_VISIT

BISPHOS
Yes

<=101.5

No

BIWEEK_FIRST_VISIT

SEX

>101.5
Male

<=159.5

Female

>159.5

ETHGRP
African
American,
Asian, Jewish
(both
Ashkenazi and
Sephardic),
Jewish (neither
Ashkenazi nor
Sephardic),
Multi-Ethnic

REGION
Europe

JewishSephardic, Arab,
Hispanic,
Caucasian,
JewishAshkenazi,
American Indian

AGEINF
<=11

Middle East,
Americas, Asia,
Pacific, S.Africa,
USA

N=81 N=32 N=49 N=14 N=64
-1.717 -0.898 -1.683 -1.800 -0.781
(1.058) (1.260) (0.831) (0.776) (1.225)
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>11

BMIB
<=22.84

>22.84

N=44 N=87 N=200 N=174 N=144
-1.343 -0.359 -1.055 -0.617 - 0.387
(1.103) (1.185) (1.212) (1.094) (1.223)

REGION
Americas, Asia, Pacific, S. Africa,
Europe, USA

Middle East

BIWEEK_FIRST_VISIT

BISPHOS
Yes

No

BIWEEK_FIRST

SEX
<=101.5

>101.5
>159.5

<=159.5

Female

Male

ETHGRP
African American,
Asian, Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
Multi-Ethnic

JewishSephardic, Arab,
Hispanic,
Caucasian,
JewishAshkenazi,
American Indian

AGEINF
REGION
Europe

Middle East,
Americas, Asia,
Pacific, S.Africa,
USA

N=81

<=11

>11

BMIB
<=21.02

>21.02

N=32 N=49 N=14 N=64
N=44
N=87 N=153 N=216 N=144
-0.898 -1.683 -1.800 -0.781 -1.343
-0.359 -1.130 -0.657 -0.387
(1.058) (1.260) (0.831) (0.776) (1.225) (1.103) (1.185) (1.220) (1.120) (1.223)
-1.717
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REGION
Middle East

Americas, Asia, Pacific, S. Africa, Europe,
USA

BIWEEK_FIRST_VISIT

BISPHOS
Yes

No

BIWEEK_FIRST_VISIT

SEX
<=101.5

>101.5
Male

<=159.5

Female

>159.5

ETHGRP
African American,
Asian, Jewish (both
Ashkenazi and
Sephardic), Jewish
(neither Ashkenazi
nor Sephardic),
Multi-Ethnic

Jewish-Sephardic, Arab,
Hispanic, Caucasian,
Jewish-Ashkenazi,
American Indian

AGEINF
<=11

>11

BMIB
<=21.2

N=81 N=32 N=49 N=78 N=44
-1.717 -0.898 -1.683 -0.964 -1.343
(1.058) (1.260) (0.831) (1.218) (1.103)
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>21.2

N=87 N=168 N=206 N=144
-0.359 -1.128 -0.625 -0.387
(1.185) (1.163) (1.142) (1.223)
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